This online educational Dialogue will focus on the role of bi-specific T-cell antibodies for patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least three prior lines of therapy or are triple refractory and how to integrate these therapies in a community setting. As a result of this educational curriculum, learners should be better able to: Review the role of bispecific antibodies in the current treatment landscape of relapsed/refractory (R/R) multiple myeloma (MM); Describe strategies to optimize outcomes with bispecific antibodies for the treatment of R/R MM; Outline practical considerations for incorporating bispecific antibodies into the treatment of heavily pretreated R/R MM in the community setting. This microburst learning activity features clinical perspectives and discussion from two leading experts divided into 5 short sessions. Paired faculty discuss focused clinical evidence and best practices, often via an interdisciplinary practice approach.
- Provider:Answers in CME Inc. (AiCME)
- Activity Link: https://www.answersincme.com/RJB
- Start Date: 2025-01-31 06:00:00
- End Date: 2025-01-31 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: Regeneron Pharmaceuticals, Inc. - Amount: 158044.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all